Eupraxia Pharmaceuticals reports new RESOLVE Phase 1b/2a symptom response data
Eupraxia Pharmaceuticals (EPRX) reports symptom response data from its ongoing Phase 1b/2a RESOLVE trial, including new data on odynophagia in eosinophilic esophagitis patients.